Coherus Identifies Stealing Amgen’s Crown As Pegfilgrastim Market Leader

Plans To Avoid ‘Resorting To Disproportionate Discounting’ Of Other Biosimilars

With its Udenyca pegfilgrastim biosimilar sales plunging in 2021 amid pricing and volume pressures, Coherus is looking to balance price and share trade-offs in 2022 before the intended launch of its proposed on-body injector device next year – in turn aiming to become the eventual pegfilgrastim market leader.

Arrows
Coherus is aiming to rise above innovator Amgen • Source: Shutterstock

Coherus BioSciences, Inc. has made clear its ambitions for the firm’s Udenyca (pegfilgrastim-cbqv) biosimilar, considering the progress towards commercialization for its own proposed on-body injector device that would rival Amgen’s market-leading Neulasta Onpro brand.

“Because of our on-body injector and our position within the pre-filled syringe marketplace, our vision for this brand is to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.